In our study, the reason why anti-EGFR antibodies combined with oxaliplatin-based chemotherapy did not show clinical benefit in wild type KRAS m-CRC remains unknown, while one plausible explanation is the nature and interaction of drugs used in combination. The gene discussed is KRAS; the disease is colorectal carcinoma.